RIV Capital Inc.
RIV.CN · Canadian Securities Exchange · CAD
0,10CAD
−0,005 (−4,76 %)Stand 19. Dez., 17:55
Kennzahlen
- Eröffnung
- –
- Vortag
- 0,105
- Tagesspanne
- 0,10 – 0,10
- 52 Wochen
- 0,10 – 0,23
- Ø Volumen
- 45.692
- Börsenwert
- 13,7 Mio. CAD
- KGV
- -0,1
- Gewinn je Aktie (TTM)
- -0,92
- Dividendenrendite
- 0,0 %
- Beta
- 0,6
- Nächste Zahlen
- –
Finanzen
| USD | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Umsatz | 6,81 Mio. | 13,43 Mio. | 10,1 Mio. | 8,13 Mio. | 3,16 Mio. |
| Herstellungskosten | 4,37 Mio. | 53,66 Mio. | 53,63 Mio. | 0 | 0 |
| Bruttogewinn | 2,44 Mio. | −40,23 Mio. | −43,53 Mio. | 4,87 Mio. | 54,78 Mio. |
| Forschung und Entwicklung | 0 | −21 | −9 | 0 | 0 |
| Vertrieb und Verwaltung | 18,32 Mio. | 7,76 Mio. | 6,09 Mio. | 13,02 Mio. | 22,81 Mio. |
| Operatives Ergebnis | −11,82 Mio. | −24,38 Mio. | −24,64 Mio. | 8,03 Mio. | 46,81 Mio. |
| EBITDA | −44,96 Mio. | −24,16 Mio. | −24,46 Mio. | 10,36 Mio. | 72,39 Mio. |
| Nettogewinn | −179,26 Mio. | −42,21 Mio. | −106,01 Mio. | −28,59 Mio. | 2,93 Mio. |
| Gewinn je Aktie (verwässert) | -1,09 | -0,30 | -0,75 | -0,15 | 0,02 |
Bewertung
Letzte 12 Monate
- KGV
- -0,1
- Kurs-Umsatz-Verhältnis
- 1,4
- Kurs-Buchwert-Verhältnis
- 0,1
- PEG
- 0,0
- Bruttomarge
- 35,8 %
- Operative Marge
- −173,6 %
- Nettomarge
- −2.633,5 %
- Verschuldungsgrad
- 1,0
- EV/EBITDA
- -0,9
- Eigenkapitalrendite
- −96,0 %
- Kapitalrendite (ROIC)
- −2,0 %
- Free-Cashflow-Rendite
- −290,7 %
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | |
|---|---|---|---|---|---|
| Bruttomarge | 35,8 % | −299,5 % | −431,1 % | 59,9 % | 1.731,0 % |
| Operative Marge | −173,6 % | −181,5 % | −244,0 % | 98,8 % | 1.479,1 % |
| Nettomarge | −2.633,5 % | −314,3 % | −1.049,8 % | −351,7 % | 92,7 % |
| KGV | -0,1 | -4,8 | -3,1 | -6,0 | 222,7 |
| Kurs-Umsatz-Verhältnis | 2,9 | 15,4 | 32,8 | 20,9 | 206,9 |
| Kurs-Buchwert-Verhältnis | 0,2 | 0,8 | 1,3 | 0,8 | 2,1 |
| Verschuldungsgrad | 1,0 | 0,3 | 0,0 | 0,0 | 0,0 |
| Liquidität 3. Grades | 83,7 | 83,7 | 61,8 | 13,1 | 14,9 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 52,54 Mio. | −31,67 Mio. | 230,13 Mio. | 137 Mio. | 577,2 Mio. |
| EV/EBITDA | -1,2 | 1,3 | -9,4 | 13,2 | 8,0 |
| Eigenkapitalrendite | −164,7 % | −15,9 % | −43,0 % | −13,6 % | 1,0 % |
| Kapitalrendite (ROIC) | −2,0 % | −5,6 % | −9,3 % | 2,2 % | 12,9 % |
| Free-Cashflow-Rendite | −141,7 % | −10,5 % | −2,0 % | −3,2 % | −0,3 % |
Wachstum
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | |
|---|---|---|---|---|---|
| Umsatz | −49,3 % | +33,0 % | +24,2 % | +156,9 % | −95,5 % |
| Bruttogewinn | +106,1 % | +7,6 % | −994,4 % | −91,1 % | −22,5 % |
| Operatives Ergebnis | +51,5 % | +1,1 % | −407,0 % | −82,9 % | −22,5 % |
| Nettogewinn | −324,7 % | +60,2 % | −270,8 % | −1.074,4 % | +6.794,8 % |
| Gewinn je Aktie | −263,3 % | +60,0 % | −400,0 % | −952,3 % | +4.500,0 % |
| Freier Cashflow | −28,4 % | −234,4 % | −20,3 % | −174,0 % | −22.240,3 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
| Nov. 2024 | Aug. 2024 | Apr. 2024 | März 2024 | Nov. 2023 | Aug. 2023 | Juni 2023 | März 2023 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | – | – | – | – | – | – | – | -0,02 |
| Gewinn je Aktie · Tatsächlich | -0,62 | -0,08 | -0,05 | -0,48 | -0,07 | -0,09 | -0,20 | -0,08 |
| Abweichung | – | – | – | – | – | – | – | −287,38 % |
| Umsatz · Tatsächlich | 6,59 Mio. | 5,18 Mio. | 2,9 Mio. | 2,81 Mio. | 3,12 Mio. | 2,37 Mio. | 2,29 Mio. | 2,56 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
- 20. Sept. 201837:1000
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
AH.TOAleafia Health Inc.0,02+33,33 %
CHAL.CNChalice Brands Ltd.0,2250,00 %
DOC.VCloudMD Software & Services Inc.0,04+14,29 %
EXM.CNEXMceuticals Inc.0,200,00 %
FAF.TOFire & Flower Holdings Corp.0,290,00 %
IMV.TOIMV Inc.1,120,00 %
KHRN.VKhiron Life Sciences Corp.0,040,00 %
MRV.TOMarvell Technology, Inc.26,56−2,42 %
Über das Unternehmen
RIV Capital Inc., formerly known as Canopy Rivers Inc., operates as a venture capital firm with a versatile investment approach. While open to opportunities across all company stages, from initial seed funding through commercialization, its primary focus is on Series A through C financing rounds. The firm's strategic interest is firmly rooted in the burgeoning cannabis sector, actively seeking out promising marijuana-related businesses and adjacent industries. Its comprehensive investment scope encompasses a wide array of areas: Agriculture and food sciences: Spanning plant, soil, food, animal, and environmental science. Production: Including diverse cultivation methods such as indoor, greenhouse, outdoor, and nursery, alongside fermentation. Processing: Involving harvesting, extraction, purification, packaging, food and beverage processing, and laboratory testing services. Pharmaceuticals and biotechnology: Covering drug discovery and development, various delivery methods (e.g., pills, soft gels, tinctures), biosynthetic derived cannabinoids, medical devices (e.g., inhalers), and lab equipment. Technology and consumer goods: Such as software and data, specialized hardware, consumer products and accessories (e.g., edibles, beverages, inhalables, cosmetics, cannabis consumption tools), and wellness products. Market access: Including retail and distribution channels (licensed brick-and-mortar stores, pharmacies, online marketplaces, delivery services), and media and content creation. Furthermore, specific product categories of interest include beverages, capsules, concentrates, edibles, dry flower/pre-rolls, vaporizers and associated hardware, pet products, and topicals. RIV Capital actively pursues investment prospects on a global scale. While check sizes have historically ranged from CA$1 million (approximately $0.71 million USD) to CA$40 million (around $28.45 million USD), the firm typically invests between CA$5 million (roughly $3.6 million USD) and CA$10 million (approximately $7.1 million USD). The firm generally seeks to acquire minority ownership stakes and employs a flexible array of investment instruments, including debt financing, preferred and common equity, and production-linked royalties. RIV Capital Inc. was established in 2017 and is headquartered in Toronto, Canada.
Führung
- Matthew Jonathon MundyChief Strategy Officer, General Counsel & Corporate Secretary
- Edward James Cirillo LucarelliChief Financial Officer
- David E. VautrinChief Retail Officer & Interim Chief Executive Officer
- Peter HatziioannouCo-Founder & Advisor
- Sean McNultyCo-Founder & Advisor
- CEO
- David E. Vautrin
- Mitarbeitende
- 94
- Hauptsitz
- Toronto, ON, CA
- Sektor
- Healthcare
- Branche
- Drug Manufacturers - Specialty & Generic
- Börsengang
- 20. Sept. 2018
- Website
- investors.getfluent.com
Nachrichten
Gerade keine Nachrichten zu diesem Unternehmen.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.